Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2019-04-02 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于调整收购河南海王银河医药有限公司少数股东股权协议的公告（更新后）
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the adjustment of an acquisition agreement for minority shareholders' equity in a subsidiary company. It details changes in performance targets, pricing standards, and the rationale behind these adjustments. It includes board and supervisory opinions and references to shareholder meetings for approval. The document is not a full financial report, audit report, or earnings release, nor is it a transcript or presentation. It is a regulatory announcement about a capital transaction and agreement adjustment related to acquisition terms. Therefore, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive content about the financing agreement adjustment, not merely a report publication announcement or a brief notice.
2019-04-02 Chinese
关于调整收购河南海王银河医药有限公司少数股东股权协议的更正公告
Capital/Financing Update Classification · 95% confidence The document is a correction announcement regarding a previously disclosed acquisition agreement adjustment. It clarifies specific terms related to the purchase price calculation for minority shareholder equity in a subsidiary. The document is short (1096 characters) and serves to correct a prior announcement rather than presenting new financial data or a full report. It does not contain financial statements or detailed analysis but is an update to a prior capital transaction disclosure. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2019-04-01 Chinese
关于调整收购河南海王银河医药有限公司少数股东股权协议的公告（已取消）
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the adjustment of an acquisition agreement for minority shareholders' equity in a subsidiary company. It details changes in performance targets, pricing standards, and the rationale behind these adjustments. The document includes board and supervisory opinions and references to shareholder meetings for approval. It does not contain full financial statements or comprehensive financial performance data but rather focuses on a specific transaction update and related corporate governance approvals. This fits the category of a Capital/Financing Update (CAP), as it relates to changes in acquisition terms and equity interests in subsidiaries.
2019-03-29 Chinese
关于为参股公司提供同比例担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding providing proportional guarantees for a jointly invested company, Shandong Kangli Medical Device Technology Co., Ltd. It includes details about the guarantee amount, board and supervisory opinions, and financial data of the guaranteed company. The document is a formal disclosure about a financing-related guarantee arrangement, not a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis, nor is it a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company.
2019-03-29 Chinese
关于为控股子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding guarantees provided for its controlling subsidiaries. It includes extensive information about the guarantee amounts, the subsidiaries involved, their legal representatives, registered capital, establishment dates, addresses, business scope, shareholder holdings, and key financial indicators. The document is a formal disclosure about the company's financial support commitments to its subsidiaries, including board approval details and shareholder meeting requirements. It does not contain financial statements or comprehensive financial performance reports but rather focuses on a specific corporate action related to guarantees for subsidiaries' borrowings. This type of document is best classified as a Capital/Financing Update (CAP) because it relates to the company's financing activities and guarantees provided to support subsidiary borrowings.
2019-03-29 Chinese
监事会关于第七届监事会第二十次会议相关事项的意见
Board/Management Information Classification · 95% confidence The document is a detailed opinion report from the Supervisory Board of Shenzhen Haiwang Bioengineering Co., Ltd. regarding several resolutions passed in their 20th meeting of the 7th Supervisory Board. The content focuses on investment, guarantees, and adjustments to acquisition agreements related to subsidiaries and associated companies. There is no indication that this is a full annual or interim financial report, nor is it a simple announcement or certification. The document discusses management-level decisions and opinions on corporate actions, which aligns with Board/Management Information filings. The length is 1402 characters, which is too short for a full financial report but appropriate for a management or board opinion document. Therefore, the best classification is MANG (Board/Management Information).
2019-03-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.